TDSPharm Co Ltd

TDSPharm maintains a conservative capital structure with a debt-to-equity ratio of 0.18, indicating limited leverage relative to equity. The company's liquidity position is characterized as medium risk, with a current ratio of 2.66, suggesting it can cover short-term obligations but with limited excess capacity. However, the company's free cash flow is negative at -7909902200 KRW, and capital expenditures are substantial at -12884008170 KRW, indicating significant reinvestment in operations. Profitability metrics show a return on equity of 9.99% and a return on assets of 7.89%, both above the typical thresholds for the pharmaceutical industry, suggesting strong asset utilization and profitability. The company's operating margin is 13.63% (3765191760 / 27620873510), and net margin is 15.47% (4274532710 / 27620873510), both of which are robust indicators of operational efficiency. TDSPharm's revenue is concentrated in its core pharmaceutical and medical equipment segments, with no disclosed geographic diversification in the provided data. The e-commerce business is a secondary contributor, but the company's primary revenue stream remains domestic pharmaceutical sales. There is no indication of significant international exposure in the current financial data. The company's growth trajectory is not explicitly outlined in the provided data, but the substantial capital expenditures suggest a strategy of expansion or modernization. The outlook for the current fiscal year is not provided, but the negative free cash flow and high capital expenditures indicate a period of reinvestment rather than immediate growth. Risk factors include the company's negative net cash position after subtracting total debt, which could limit flexibility in the event of a liquidity crunch. The dilution risk is assessed as low, with no near-term pressure expected, and the company's capital structure remains stable. The company's liquidity risk is moderate, with a current ratio of 2.66, but the negative free cash flow and high capital expenditures could strain liquidity in the near term. Recent events are not detailed in the provided data, but the company's financial filings indicate a focus on capital expenditures and reinvestment in operations. There are no disclosed regulatory or geopolitical risks in the current data, but the pharmaceutical industry is subject to regulatory changes and supply chain disruptions.